LOS ANGELES--(BUSINESS WIRE)--Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) today announced that it has completed its planned name change of the corporation to Abviva, Inc. Genesis Bioventures changed its corporate name to Abviva, Inc. to emphasize its mission to commercialize the Mammastatin Serum Assay (“MSA”) and to pursue development of the mammastatin protein as a possible first line therapy against breast cancer. The name change was approved by the shareholders at the 2007 Annual Shareholders Meeting held on September 14, 2007 as part of the Company’s completion of its reorganization and restructuring plan.
